Michael Burgess actually said...

"I thought that was a serious and glaring oversight on the part of this committee."

"I was concerned about some of the restrictions that this committee placed on the advisory panels that advise the FDA about the approval or non-approval of drugs and devices."

"I hope we will be serious about fixing this."

"It is, I think, incumbent upon us to get that right."